Mon. Apr 13th, 2026

BRIEF-Janssen Pharmaceuticals terminates licensing agreement with Amgen for Fulranumab

ByReuters: Market News

Mar 31, 2016 nasdaq

* Janssen announces discontinuation of Fulranumab phase 3 development program in Osteoarthritis pain

The post BRIEF-Janssen Pharmaceuticals terminates licensing agreement with Amgen for Fulranumab appeared first on NASDAQ.

By Reuters: Market News

Related Post

Unlock the Profits of the Forex Market with Winning Strategies

May 28, 2023 admin

Master the Art of Forex Trading with These Proven Strategies

May 28, 2023 admin

Take Control of Your Investments with Strategic Forex Trading Strategies

May 28, 2023 admin

You missed

South Korea’s Crypto Oversight: Circuit Breakers on the Horizon After Bithumb Glitch

Apr 13, 2026 admin

US Crypto Regulation Heats Up: Coinbase CEO Joins Treasury Calls for Clarity Act – What Traders Need to Know

Apr 13, 2026 admin

Bitcoin’s Bullish Reversal: Stablecoin Exodus Signals Renewed Crypto Momentum

Apr 13, 2026 admin

Trump-Linked Crypto Project Under Fire: Are Your Funds Safe?

Apr 13, 2026 admin